Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

Dr Lenz on the Prognostic Value of HER2 Expression in mCRC

April 19th 2024

Heinz-Josef Lenz, MD, FACP, discusses the prognostic value of HER2 expression in patients with KRAS wild-type metastatic colorectal cancer.

Dr. Lenz on the Rationale for the CheckMate 9X8 Trial in Metastatic CRC

January 20th 2022

Heinz-Josef Lenz, MD, FACP, discusses the rationale for the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer.

Future Directions in Later Line Therapy for mCRC

June 29th 2020

Key Trials in mCRC: I/O Combination Therapies

June 29th 2020

Role of I/O Combination Therapies in mCRC

June 29th 2020

Using I/O in MSI-H Tumors in mCRC

June 29th 2020

Sequencing in mCRC: Later-Line Therapies

June 29th 2020

Therapeutic Agents in Relapsed/Refractory mCRC

June 29th 2020

CORRECT, RECOURSE, and ReDOS Trials in mCRC

June 29th 2020

Later Lines of Therapy for mCRC

June 29th 2020

Second-Line Treatment for mCRC

June 29th 2020

Initiating Therapy for mCRC

June 29th 2020

Continuum of Care for Metastatic CRC

June 29th 2020

Dr. Lenz on the Updated Findings From the CheckMate-142 Trial in mCRC

June 4th 2020

Heinz-Josef Lenz, MD, FACP, discusses the updated findings from the phase 2 CheckMate-142 trial in previously untreated patients with microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).

Dr. Lenz on Updated Results of the CheckMate-142 Trial in mCRC

September 25th 2019

Heinz-Josef Lenz, MD, FACP, discusses updated results from the phase II CheckMate-142 trial in metastatic colorectal cancer.

Dr. Lenz on the Safety Profile in CheckMate-142 Trial in CRC

August 28th 2019

Heinz-Josef Lenz, MD, FACP, discusses the safety profile of nivolumab plus ipilimumab in the phase II CheckMate-142 trial for treatment-naïve patients with microsatellite instability–high/mismatch repair deficient colorectal cancer.

Dr. Lenz on Need for New Treatment Strategies in Colorectal Cancer

August 11th 2017

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the need for new treatment strategies in colorectal cancer.

Dr. Lenz Discusses Targeted Combinations in Colorectal Cancer

July 13th 2017

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses combinations with targeted agents in colorectal cancer.

Dr. Lenz Discusses Immunotherapy in Gastrointestinal Cancers

July 1st 2017

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses immunotherapy in gastrointestinal cancers.